HTLV-III/LAV FOR POTENTIAL USE AS A RECOMBINANT SUBUNIT VACCINE

Award Information

Agency: Department of Health and Human Services

Branch: N/A

Contract: N/A

Agency Tracking Number: 4791

Amount: $50,000.00

Phase: Phase I

Program: SBIR

Solicitation Topic Code: N/A

Solicitation Number: N/A

Timeline

Solicitation Year: N/A

Award Year: 1986

Award Start Date (Proposal Award Date): N/A

Award End Date (Contract End Date): N/A

Small Business Information

NEUGENESIS CORPORATION

871 Industrial Road Building J

San Carlos, CA 94070

United States

DUNS: N/A

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: No

Principal Investigator

Name: GREGORY R REYES
Title: PRINCIPAL INVESTIGATOR
Phone: (415) 594-1600

Business Contact

Phone: () -

Research Institution

N/A

Abstract

HTLV-III/LAV IS A RECENTLY DESCRIBED HUMAN RETROVIRUS LINKEDBOTH MOLECULAR- AND SEROEPIDEMIOLOGICALLY TO THE CURRENT EPIDEMIC OF AIDS. IT SHOULD BE POSSIBLE NOT ONLY TO INTERFERE WITH VIRAL PROPOGATION IN A CHEMOTHERAPEUTIC MANNER BUT ALSO TO EFFECT IMMUNOPROPHYLAXIS IN THE AT-RISK POPULATION, AS THE SYNDROME HAS AN INFECTIOUS ETIOLOGY. THEAIM OF THIS PROJECT IS TO IDENTIFY VIRALLY ENCODED ANTIGENICDETERMINANTS THAT ARE PRODUCED IN A RECOMBINANT DNA EXPRESSION VECTOR BY IMMUNOSCREENING PROTOCOLS. WELL- CHARACTERIZED RECOMBINANT HTLV-III ANTIGENS MAY SERVE AS SEROTYPIC MARKERS OF DISEASE AND WILL BE ASSAYED FOR THEIR EFFECT IN BLOCKING IN VITRO MEASURES OF NEUTRALIZATION. A RECOMBINANT EPITOPE EFFECTIVE IN THE LATTER ASSAY WOULD BE APRIME CANDIDATE FOR A RECOMBINANT SUBUNIT VACCINE.

* Information listed above is at the time of submission. *

You are here

HTLV-III/LAV FOR POTENTIAL USE AS A RECOMBINANT SUBUNIT VACCINE